Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined application of sequential infusion CD19 CAR-T and BCMA CAR-T cells in immune-mediated platelet infusion invalidation of acute leukemia patients

An acute leukemia, combined application technology, applied in the direction of medical preparations containing active ingredients, drug combinations, antibody medical ingredients, etc., to achieve the effect of improving the ineffectiveness of infusion

Pending Publication Date: 2022-05-31
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is expressed throughout differentiation from pre-B cells to mature B cells, but available evidence suggests that the majority of LLPCs are CD19-negative

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined application of sequential infusion CD19 CAR-T and BCMA CAR-T cells in immune-mediated platelet infusion invalidation of acute leukemia patients
  • Combined application of sequential infusion CD19 CAR-T and BCMA CAR-T cells in immune-mediated platelet infusion invalidation of acute leukemia patients
  • Combined application of sequential infusion CD19 CAR-T and BCMA CAR-T cells in immune-mediated platelet infusion invalidation of acute leukemia patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] The present invention will be further described below in conjunction with specific cases.

[0033] Case 1:

[0034] A 38-year-old female patient was diagnosed with acute myeloid leukemia (M2) and had a history of pregnancy. She visited the doctor due to fever in September 2019. The blood routine showed: WBC 5.97×10 9 / L,NE 3.62×10 9 / L, HB 69g / L, PLT 13×10 9 / L, transferred to the local hospital for blood transfusion and other comprehensive treatment, 09-16 complete bone wear, morphology: high level of active bone marrow hyperplasia, 20.5% of protocells, AML-M2 not excluded; white immunity: analysis of 26.6% of immature The cell population was expressed for myeloid antigens, and 57.5% of myeloid differentiation antigens were abnormally expressed, which was in line with the AML-M2 phenotype, so he went to our hospital. Check peripheral blood original young 22%. Chromosome: 46XX, t(8;21)(q22;q22)[7] / 45, idem, -X[3]. Bone marrow multiplex PCR: AML1-ETO fusion gene tra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a combined application of sequential infusion of CD19 CAR-T and BCMA CAR-T cells in immune-mediated platelet infusion invalidation (PTR) of acute leukemia patients, and is characterized in that the combined application is as follows: the infusion dose of the CD19 CAR-T cells is (1.0-2.0) * 10 < 7 > / kg, the infusion dose of the BCMA CAR-T cells is (1.0-2.0) * 10 < 7 > / kg, the infusion dose of the BCMA CAR-T cells is (1.0-2.0) * 10 < 7 > / kg, and the infusion dose of the BCMA CAR-T cells is (1.0-2.0) * 10 < 7 > / kg. According to the BCMA CAR-T cells, the infusion dosage is (1.0-2.0) * 10 < 7 > / kg. The CD19 CAR-T and BCMA CAR-T cells are sequentially infused, so that the platelet infusion ineffectiveness of an immune-mediated PTR patient is improved, the platelet usage amount is reduced, and the death risk caused by bleeding is reduced; the average hospitalization day is shortened; the economic burden of patients is relieved; the social problem that blood product resources are seriously deficient is relieved; meanwhile, the generation of HLA related antibodies and donor specific HLA antibodies can be reduced, the death possibility of patients caused by major hemorrhage complications caused by hemorrhage in subsequent chemotherapy and transplantation due to invalid platelet infusion is reduced, and implantation failure after allogenic hematopoietic stem cell transplantation is prevented.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the combined application of sequential infusion of CD19 CAR-T and BCMA CAR-T cells in patients with acute leukemia in whom immune-mediated platelet transfusion is ineffective. Background technique [0002] Platelet transfusion ineffectiveness (Platelet Transfusion Refractoriness, PTR) means that after two or more platelet transfusions with ABO blood group matching and storage time less than 72 hours, the increase of platelet count is not obvious or not increased, or even higher than that of transfused platelets. Pre-decline of platelets. The causes of PTR include non-immune factors and immune factors. Non-immune factors include fever, infection, splenomegaly, disseminated intravascular coagulation, graft-versus-host disease, and certain drugs; immune factors include ABO blood group incompatibility, Anti-human leukocyte antigen (Human Leukocyte Antigen, HLA) antibody and / or anti-huma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P35/02
CPCA61K39/001112A61K39/001117A61P35/02
Inventor 唐晓文吴德沛俞磊戴海萍崔庆亚崔巍尹佳康立清杨春秀
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com